Basilea Pharmaceutica AG (BSLN.SW)
CHF 41.65
(0.24%)
CHF 41.65
(0.24%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 0.87 CHF | -14.71% |
| 2022 | 1.02 CHF | 275.86% |
| 2021 | -0.58 CHF | 59.44% |
| 2020 | -1.43 CHF | 31.25% |
| 2019 | -2.08 CHF | 28.03% |
| 2018 | -2.89 CHF | -61.45% |
| 2017 | -1.79 CHF | 64.69% |
| 2016 | -5.07 CHF | 16.75% |
| 2015 | -6.09 CHF | -46.04% |
| 2014 | -4.17 CHF | -22.65% |
| 2013 | -3.40 CHF | 38.52% |
| 2012 | -5.53 CHF | 7.99% |
| 2011 | -6.01 CHF | -153.71% |
| 2010 | 11.19 CHF | 188.74% |
| 2009 | -12.61 CHF | 16.05% |
| 2008 | -15.02 CHF | -7.52% |
| 2007 | -13.97 CHF | -26.54% |
| 2006 | -11.04 CHF | -65.77% |
| 2005 | -6.66 CHF | 38.67% |
| 2004 | -10.86 CHF | -1.4% |
| 2003 | -10.71 CHF | 8.54% |
| 2002 | -11.71 CHF | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 1.72 CHF | 0.0% |
| 2023 Q4 | -1.78 CHF | 0.0% |
| 2023 Q2 | 2.66 CHF | 0.0% |
| 2023 FY | - CHF | -14.71% |
| 2022 Q4 | 2.04 CHF | 0.0% |
| 2022 Q2 | -1.03 CHF | 0.0% |
| 2022 FY | - CHF | 275.86% |
| 2021 Q2 | -1.72 CHF | 0.0% |
| 2021 Q4 | 1.10 CHF | 0.0% |
| 2021 FY | - CHF | 59.44% |
| 2020 Q2 | 0.92 CHF | 0.0% |
| 2020 FY | - CHF | 31.25% |
| 2020 Q4 | -2.27 CHF | 0.0% |
| 2019 Q4 | -0.65 CHF | 0.0% |
| 2019 Q2 | -1.44 CHF | 0.0% |
| 2019 FY | - CHF | 28.03% |
| 2018 FY | - CHF | -61.45% |
| 2018 Q2 | -2.07 CHF | 0.0% |
| 2018 Q4 | -0.81 CHF | 0.0% |
| 2017 Q2 | -1.90 CHF | 0.0% |
| 2017 Q4 | 0.11 CHF | 0.0% |
| 2017 FY | - CHF | 64.69% |
| 2016 Q2 | -2.76 CHF | 0.0% |
| 2016 FY | - CHF | 16.75% |
| 2016 Q4 | -2.31 CHF | 0.0% |
| 2015 Q2 | -3.00 CHF | 0.0% |
| 2015 Q4 | -3.09 CHF | 0.0% |
| 2015 FY | - CHF | -46.04% |
| 2014 Q4 | -2.21 CHF | 0.0% |
| 2014 FY | - CHF | -22.65% |
| 2014 Q2 | -1.97 CHF | 0.0% |
| 2013 Q4 | -1.60 CHF | 0.0% |
| 2013 Q2 | -1.80 CHF | 0.0% |
| 2013 FY | - CHF | 38.52% |
| 2012 Q2 | -1.38 CHF | 0.0% |
| 2012 Q1 | -1.38 CHF | 0.0% |
| 2012 Q4 | -0.85 CHF | 38.41% |
| 2012 FY | - CHF | 7.99% |
| 2012 Q3 | -1.38 CHF | 0.0% |
| 2011 FY | - CHF | -153.71% |
| 2011 Q3 | -1.50 CHF | 0.0% |
| 2011 Q4 | -1.38 CHF | 8.0% |
| 2011 Q2 | -1.50 CHF | 0.0% |
| 2011 Q1 | -1.50 CHF | 0.0% |
| 2010 Q4 | -1.50 CHF | -153.57% |
| 2010 FY | - CHF | 188.74% |
| 2010 Q2 | 2.80 CHF | 0.0% |
| 2010 Q1 | 2.80 CHF | 0.0% |
| 2010 Q3 | 2.80 CHF | 0.0% |
| 2009 FY | - CHF | 16.05% |
| 2009 Q1 | -3.15 CHF | 0.0% |
| 2009 Q2 | -3.15 CHF | 0.0% |
| 2009 Q3 | -3.15 CHF | 0.0% |
| 2009 Q4 | 2.80 CHF | 188.89% |
| 2008 FY | - CHF | -7.52% |
| 2008 Q4 | -3.15 CHF | 16.22% |
| 2008 Q1 | -3.76 CHF | 0.0% |
| 2008 Q2 | -3.76 CHF | 0.0% |
| 2008 Q3 | -3.76 CHF | 0.0% |
| 2007 Q2 | -3.49 CHF | 0.0% |
| 2007 Q4 | -3.76 CHF | -7.74% |
| 2007 Q3 | -3.49 CHF | 0.0% |
| 2007 Q1 | -3.49 CHF | 0.0% |
| 2007 FY | - CHF | -26.54% |
| 2006 Q2 | -2.76 CHF | 0.0% |
| 2006 Q3 | -2.76 CHF | 0.0% |
| 2006 Q4 | -3.49 CHF | -26.45% |
| 2006 FY | - CHF | -65.77% |
| 2006 Q1 | -2.76 CHF | 0.0% |
| 2005 Q4 | -2.76 CHF | -65.27% |
| 2005 Q3 | -1.67 CHF | 0.0% |
| 2005 Q1 | -1.67 CHF | 0.0% |
| 2005 Q2 | -1.67 CHF | 0.0% |
| 2005 FY | - CHF | 38.67% |
| 2004 FY | - CHF | -1.4% |
| 2004 Q1 | -2.71 CHF | 0.0% |
| 2004 Q2 | -2.71 CHF | 0.0% |
| 2004 Q3 | -2.71 CHF | 0.0% |
| 2004 Q4 | -1.67 CHF | 38.38% |
| 2003 Q1 | -2.68 CHF | 0.0% |
| 2003 Q3 | -2.68 CHF | 0.0% |
| 2003 Q4 | -2.71 CHF | -1.12% |
| 2003 Q2 | -2.68 CHF | 0.0% |
| 2003 FY | - CHF | 8.54% |
| 2002 Q3 | -2.93 CHF | 0.0% |
| 2002 FY | - CHF | 0.0% |
| 2002 Q2 | -2.93 CHF | 0.0% |
| 2002 Q1 | -2.93 CHF | 0.0% |
| 2002 Q4 | -2.68 CHF | 8.53% |
| 2001 Q4 | -2.93 CHF | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Addex Therapeutics Ltd | -0.14 CHF | 721.429% |
| BB Biotech AG | -3.77 CHF | 123.077% |
| Evolva Holding SA | -19.50 CHF | 104.462% |
| Idorsia Ltd | -1.67 CHF | 152.096% |
| Kuros Biosciences AG | -0.38 CHF | 328.947% |
| Molecular Partners AG | -1.89 CHF | 146.032% |
| Relief Therapeutics Holding AG | -8.35 CHF | 110.419% |
| Santhera Pharmaceuticals Holding AG | 5.18 CHF | 83.205% |